166 related articles for article (PubMed ID: 32930584)
1. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
Fairhurst RA; Knoepfel T; Buschmann N; Leblanc C; Mah R; Todorov M; Nimsgern P; Ripoche S; Niklaus M; Warin N; Luu VH; Madoerin M; Wirth J; Graus-Porta D; Weiss A; Kiffe M; Wartmann M; Kinyamu-Akunda J; Sterker D; Stamm C; Adler F; Buhles A; Schadt H; Couttet P; Blank J; Galuba I; Trappe J; Voshol J; Ostermann N; Zou C; Berghausen J; Del Rio Espinola A; Jahnke W; Furet P
J Med Chem; 2020 Nov; 63(21):12542-12573. PubMed ID: 32930584
[TBL] [Abstract][Full Text] [Related]
2. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
5. Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.
Zhou Z; Chen X; Fu Y; Zhang Y; Dai S; Li J; Chen L; Xu G; Chen Z; Chen Y
Chem Commun (Camb); 2019 May; 55(42):5890-5893. PubMed ID: 31041948
[TBL] [Abstract][Full Text] [Related]
6. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
[TBL] [Abstract][Full Text] [Related]
7. Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S
Schwarz M; Kurkunov M; Wittlinger F; Rudalska R; Wang G; Schwalm MP; Rasch A; Wagner B; Laufer SA; Knapp S; Dauch D; Gehringer M
J Med Chem; 2024 Apr; 67(8):6549-6569. PubMed ID: 38604131
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
10. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
11. Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation.
Schadt HS; Wolf A; Mahl JA; Wuersch K; Couttet P; Schwald M; Fischer A; Lienard M; Emotte C; Teng CH; Skuba E; Richardson TA; Manenti L; Weiss A; Graus Porta D; Fairhurst RA; Kullak-Ublick GA; Chibout SD; Pognan F; Kluwe W; Kinyamu-Akunda J
Toxicol Sci; 2018 May; 163(1):265-278. PubMed ID: 29432567
[TBL] [Abstract][Full Text] [Related]
12. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
14. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
Shao M; Chen X; Yang F; Song X; Zhou Y; Lin Q; Fu Y; Ortega R; Lin X; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Mar; 65(6):5113-5133. PubMed ID: 35271262
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
Wang Y; Chen Z; Dai M; Sun P; Wang C; Gao Y; Zhao H; Zeng W; Shen L; Mao W; Wang T; Hu G; Li J; Chen S; Long C; Chen X; Liu J; Zhang Y
Bioorg Med Chem Lett; 2017 Jun; 27(11):2420-2423. PubMed ID: 28433531
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.
Zhang Z; Li J; Chen H; Huang J; Song X; Tu ZC; Zhang Z; Peng L; Zhou Y; Ding K
J Med Chem; 2022 Feb; 65(4):3249-3265. PubMed ID: 35119278
[TBL] [Abstract][Full Text] [Related]
18. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
Tao Z; Cui Y; Xu X; Han T
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
[TBL] [Abstract][Full Text] [Related]
20. Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies.
Sun C; Fang L; Zhang X; Gao P; Gou S
Bioorg Med Chem; 2019 May; 27(10):1932-1941. PubMed ID: 30987781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
